Various strategies of vendors in the global Duchenne muscular dystrophy therapeutics market.

The global Duchenne muscular dystrophy therapeutics market is expected to grow at a CAGR of 37.11% during the forecast period. Major vendors in the global Duchenne muscular dystrophy therapeutics market include F. Hoffmann-La Roche Ltd., PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., and Wave Life Sciences Ltd.

Vendors are focusing on strategies such as M&A and partnerships to increase their reach and share in the market. For instance, F. Hoffmann-La Roche Ltd., in February 2019, the company entered into a definitive merger agreement to acquire Spark Therapeutics Inc. PTC Therapeutics Inc., in May 2019, the company entered into a strategic collaboration agreement with MRI Interventions Inc. (MRI) for the development of highly effective therapeutics using MRI’s neurosurgical devices and PTC Therapeutics’ gene therapy programs.

Request for: Free Sample Report

Santhera Pharmaceuticals, in May 2019, the company entered into a license agreement with Chiesi Farmaceutici S.p.A. for Raxone for the treatment of Leber’s hereditary optic neuropathy. Sarepta Therapeutics Inc., in May 2019, the company entered into an agreement with the Research Institute at Nationwide Children’s Hospital for the rights to its gene therapy program to treat limb-girdle muscular dystrophy type 2A. Therefore, the increasing number of M&A and partnerships among vendors is likely to augment the growth of the global Duchenne muscular dystrophy therapeutics market during the forecast period.